Supplementary Table. Baseline Demographic and Disease Characteristics of Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients (EPIC-HR) and Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR) Study Participants — United States and International Sites, 2021–2022

Advanced Search

Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

Advanced Search
Custom Query

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Clear All

Query Builder

Query box

Clear All

For additional assistance using the Custom Query please check out our Help Page

CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners. As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.

i

Supplementary Table. Baseline Demographic and Disease Characteristics of Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients (EPIC-HR) and Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR) Study Participants — United States and International Sites, 2021–2022

12/22/2023
By Centers for Disease Control and Prevention (U.S.)
Source: MMWR: Morbidity and Mortality Weekly Report 2023; v. 72, no. 51
Series: Weekly Report: Morbidity and Mortality Weekly Report (MMWR)

English

Details Related Documents You May Also Like

Details:

Alternative Title:

Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials — United States and International Sites, 2021–2022: Supplementary Table. Baseline Demographic and Disease Characteristics of Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients (EPIC-HR) and Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR) Study Participants — United States and International Sites, 2021–2022
Corporate Authors:

Centers for Disease Control and Prevention (U.S.)
Source:

MMWR: Morbidity and Mortality Weekly Report 2023; v. 72, no. 51
Series:

Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
ISSN:

0149-2195 (print);1545-861X (digital);
Document Type:

Journal Article
Place as Subject:

United States
Pages in Document:

2 pdf page
Volume:

72
Issue:

51
Collection(s):

Morbidity and Mortality Weekly Report (MMWR)
Main Document Checksum:

[+]

urn:sha-512:33ad10014d4d8f57eda9caa556634f3f6a2beec90e9295bb0fb00ab2e18e95c2081489fb4771ff0e58da264c05040bfa83f84baee5f50ae7b7973b060c366a34
Download URL:

https://stacks.cdc.gov/view/cdc/136166/cdc_136166_DS1.pdf
File Type:

[PDF-200.40 KB]